Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the ...

Modern OCT devices can look inside the eye without a scalpel - but they do not always capture everything that matters. Some ...

Modern OCT devices can look inside the eye without a scalpel - but they do not always capture everything that matters. Some critical information is ...

Top line data readout expected in late Q3/early Q4; INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...

A new approach for identifying signs of hidden awareness in people who cannot speak or move after severe brain injury has ...

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today provides shareholders a ...

The wAIHA market landscape is undergoing a significant evolution after years of dependence on broad immunosuppressive ...

Advances in soft materials are reshaping the design of next-generation devices, particularly where flexibility, adaptability, ...

Company’s presentation will provide updates on SkinJect® Phase 2b Pivotal Study in patients with Gorlin Syndrome and Teverelix® Groundbreaking PRECISION-E2 Phase 2a Endometriosis Study leveraging the ...

Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer Novel immunotherapy technology demonstrating ...

BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC) ...